Sector News

Horizon Pharma buys River Vision

May 8, 2017
Food & Drink

Just seven months after Horizon Pharma’s $800 million Raptor rare disease buy, the Irish biotech is spending $145 million, plus biobucks, for River Vision and its inflammatory eye drug teprotumumab.

The buyout of River Vision, which was founded by Narrow River Management, centers on its asset teprotumumab (RV001), a fully human mAb inhibitor of insulin-like growth factor type 1 receptor, in tests for thyroid eye disease (TED), a rare autoimmune inflammatory disorder.

Horizon Pharma will stump up a cash payment of $145 million, plus potential future milestone bonuses; it hopes to gain that money back and then some, as it sees the drug, should it gain approval (and it already has an FDA fast-track tag), making $250 million-plus in the U.S. at peak.

“This acquisition is an important step in our strategy of pursuing and acquiring development-stage medicines targeting rare diseases,” said Timothy Walbert, chairman, president and CEO at Horizon. “With no approved medicines to treat Thyroid Eye Disease, there is a significant unmet treatment need among the approximately 10,000 patients in the United States with moderate to severe disease and we look forward to beginning the pivotal study with teprotumumab in the second half of this year.”

The deal comes a week after The New England Journal of Medicine published phase 2 data for the med, looking at teprotumumab in patients with recent-onset, moderate-to-severe TED.

The data showed that, in the intention-to-treat population, 29 of 42 patients who received teprotumumab (69%), as compared with 9 of 45 patients who received placebo (20%), had a response at week 24.

River Vision was founded by Narrow River Management for the sole purpose of developing teprotumumab, a phoenix from the flames asset, which was developed by Genmab and subsequently licensed from Roche in cancer, where it failed to make the grade.

This is the latest deal for Horizon, which last September spent $800 million on Raptor, gaining access to Procysbi (cysteamine bitartrate) for the orphan condition nephropathic (kidney) cystinosis, as well as Quinsair, which is licensed in Europe and Canada to help manage chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Blurred lines: Vitafoods Europe 2022 review

Food & Drink

Upon FoodBev Media’s return from Vitafoods 2022 – which took place from 10-12 May in Geneva, Switzerland – the team reflects on the event’s aim to bring together international nutraceutical suppliers and experts from across the globe.

May 15, 2022

Crunch time: Mondelēz to dump chewing gum to take bigger bite of chocolate and biscuits markets

Food & Drink

Following a strategic review last year, Mondelēz International is planning to sell its developed chewing gum business, which includes brands Trident and Dentyne. This is in addition to offloading its Halls cough drop brand, as the food giant focuses on generating 90% of revenue in its chocolates and biscuits businesses, including baked snacks.

May 15, 2022

Givaudan strengthens natural preservation portfolio with nitrite alternative for processed meat

Food & Drink

Givaudan has unveiled NaNino+, a patent-pending combination of plant-based ingredients and natural flavorings that can replace nitrite in processed meat. Designed with natural ingredients, it provides a lasting multi-sensorial food experience with a good taste, color and freshness.